CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial

CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial

Abstract Background A substantial proportion of breast cancer patients develop metastatic disease, with over 450,000 deaths globally per year. Bone is the most common first site of metastatic disease accounting for 40% of all first recurrence and 70% of patients with advanced disease develop skeleta...

Full description

Bibliographic Details
Main Authors: Rob Coleman, Janet Brown, Emma Rathbone, Louise Flanagan, Amber Reid, Jessica Kendall, Sacha Howell, Chris Twelves, Carlo Palmieri, Anjana Anand, Iain MacPherson, Sarah Brown
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Trials
Subjects:
Radium-223
Capecitabine
Bone metastases
Bone turnover markers
Breast cancer
Online Access:https://doi.org/10.1186/s13063-019-3643-6

Internet

https://doi.org/10.1186/s13063-019-3643-6

Similar Items